Biotech Values

[mcbio]

I may listen to a webcast or two to see if ALNY has the makings of a turnaround story.

I will do the same. I agree it merits a bit further scrutiny given the large drop, good cash balance, and extensive platform technology and patents. I will say that I haven't been too impressed with the clinical results to date from their lead drug ALN-RSV01 (http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38509875 and http://investorshub.advfn.com/boards/replies.aspx?msg=38509875 ). This drug is in a Phase 2b now so I might be more interested assuming more negative data from this trial and a further drop in share price. ALNY is working on a 2nd gen version of this drug, apparently, that has yet to enter the clinic.